The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

Recruiting

• Conditions: Esophageal Cancer; Lung Cancer

• Registration Number: NCT06019455
• Lead Sponsor: Sun Yat-sen University

Brief Summary

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-01
• Study First Submitted: 2023-08-25
• Study First Submitted QC: 2023-08-25
• Study First Posted: 2023-08-31
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-05
• Last Update Posted: 2024-12-10
• Primary Completion: 2027-05-30
• Study Completion: 2027-05-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
• Planned to undergo definitive chemoradiotherapy ± immunotherapy;
• Males or females aged 18 to 75;
• Able to communicate with medical staff.

Exclusion Criteria

Patients with cognitive impairments.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of >=Grade 3 toxicities	2 years	The percentage of patients who develop \>=Grade 3 toxicities

Secondary Outcome Measures

Name	Time	Method
Overall survival	2 years	2-year survival rate
Progression-free survival	2 years	2-year progression-free survival rate

Trial Locations

Locations (1)

Sun Yat-sen University; 🇨🇳 Guangzhou, China